EGRX
Eagle Pharmaceuticals, Inc.
EGRX
EGRX
Delisted
EGRX was delisted on the 2nd of October, 2024.
153 hedge funds and large institutions have $334M invested in Eagle Pharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 53 increasing their positions, 63 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
16% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 63
Holders
153
Holding in Top 10
1
Calls
$48K
Puts
$23K
Top Buyers
1 | +$7.86M | |
2 | +$5.9M | |
3 | +$3.69M | |
4 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$3.66M |
5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.08M |
Top Sellers
1 | -$15.6M | |
2 | -$2.49M | |
3 | -$2.31M | |
4 |
ETM
Euclidean Technologies Management
Seattle,
Washington
|
-$2.11M |
5 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$1.81M |